Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $71.67.

Several brokerages have issued reports on APLS. HC Wainwright cut their target price on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Robert W. Baird boosted their price objective on Apellis Pharmaceuticals from $86.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, August 9th. Wells Fargo & Company lowered their price objective on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a research report on Thursday, May 23rd. Finally, Piper Sandler assumed coverage on Apellis Pharmaceuticals in a research report on Friday, May 31st. They issued a “neutral” rating and a $46.00 price objective for the company.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 6.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky bought a new position in Apellis Pharmaceuticals in the second quarter worth $725,000. Algert Global LLC raised its holdings in Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after purchasing an additional 71,650 shares in the last quarter. AQR Capital Management LLC raised its holdings in Apellis Pharmaceuticals by 337.3% in the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Toronto Dominion Bank raised its holdings in Apellis Pharmaceuticals by 146.0% in the second quarter. Toronto Dominion Bank now owns 24,600 shares of the company’s stock worth $944,000 after purchasing an additional 14,601 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Apellis Pharmaceuticals in the second quarter worth $2,350,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Up 0.3 %

Shares of APLS opened at $35.63 on Thursday. The firm has a market cap of $4.32 billion, a P/E ratio of -10.30 and a beta of 0.88. The stock has a 50 day simple moving average of $38.05 and a two-hundred day simple moving average of $44.06. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals has a 1 year low of $33.49 and a 1 year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. Apellis Pharmaceuticals’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.02) earnings per share. On average, analysts forecast that Apellis Pharmaceuticals will post -1.29 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).